Your Solutions
BIOMEDTRACKER
Real-time Event Tracking & Drug Development Analysis
管線研發追蹤、獲批前景分析、商業資訊、調研報告
DATAMONITOR HEALTHCARE
Disease Competitive Analysis, 10-20 Years Market Forecast, KOL Insights
疾病競爭分析、10-20年市場預測、KOL專訪
Meet the team
Julie Guan (China)
Head of Strategic Accounts
Citeline
Youmin Zhu (China)
Client Success Manager
Citeline
Training & Help
We provide product training support via online sessions/pre-recorded materials, please click below to access relevant contents, or reach out to this email for any customized training request: [email protected]
我們提供各產品的使用培訓支持，請點擊下列查閲相關培訓資源，若有特定培訓需求或安排則可聯絡：[email protected]
For access or technical issues, please contact your dedicated support team via 'Meet the Team', or contact Client Service team via below email:
若有任何登錄問題，請切換至Meet the Team版面並聯絡對接服務團隊，或可聯絡全球/亞太客服團隊：
Global - [email protected] (English only)
APAC - [email protected] (via English/Chinese)
Require Research Support?
Ask-the-Analyst™
Ask-the-Analyst™
Your status as a loyalty partner includes unlimited access to our highly acclaimed Ask-the-Analyst™ service. With a 24-hour response time, Ask-the-Analyst offers you authoritative information to help you make faster, smarter business decisions.
作爲重點合作夥伴，貴司用戶均可無限量使用「Ask-the-Analyst™」分析師咨詢服務。分析師團隊將會在24小時内回復（工作日），并爲您提供信息收集或專業見解，最終助您做出更快、更明智的業務決策。
Our Ask-the-Analyst team of industry experts leverages the complete suite of pharma intelligence products and publicly available sources to bring you the answers you’re looking for, while your information and all questions received are strictly confidential.
由業界專家組成的Ask the Analyst團隊將結合内部數據與公開領域資源爲您提供相關信息支持，您的個人資訊與提問内容均會被嚴格保密。
Latest Pharma Monthly Newsletter
Edition: June 2026
EDITORIAL CONTENTS (incl. Podcasts, Webinars)
- Podcast: Drug Fix: US FDA’s New Guidance On One-Trial Efficacy Standard And IND Reform Pilot (Listen)
- Webinar: China Pipelines, Western Portfolios (Watch Now)
- Webinar: World Preview 2026 (Watch Now)
DEALS & FINANCING (incl. M&As, Licensing, Financing)
- M&A: Merck to Acquire Bio-Techne for $11.3B
- M&A: AbbVie to Acquire Apogee Therapeutics for $10.9B
- M&A: GSK to Acquire Nuvalent for $10.6B in Cash
- Licensing: Haisco Pens Collaboration with Eli Lilly totalling $3.05B
- Licensing: Servier Acquires Edgewise’s Muscular Dystrophy Assets for up to $2.65B ($1.55B upfront)
- Licensing: Roche Enters Global Collaboration to Co-Develop and Co-Commercialize Nurix Therapeutics' Bexobrutideg totalling $2.3B ($700M upfront)
- Financing: Parabilis Medicines Nets $716.57M in Initial Public Offering
- Financing: NewLimit Closes $435M Series C Round
- Financing: Ollin Biosciences Raises $330M in Series B Round
KEY R&D EVENTS (incl. Top-line Readouts, Analyst Commentary, Approval/CRL)
- Positive: Eli Lilly | Lilly's $2.3bn Ajax bet gets its first clinical validation as AJ1-11095 posts spleen and symptom responses well above the post-JAK-inhibitor standard
- Positive: Moleculin Biotech | Compelling interim CR data support annamycin’s potential to redefine the R/R AML salvage landscape
- Positive: Zealand Pharma | Phase III success strengthens Zealand Pharma/Boehringer’s survodutide approval outlook as hepatic benefits differentiate beyond weight loss alone
- Positive: Cabaletta Bio | CD19 CAR T, Rese-Cel, showed durable response in myositis with favorable safety profile and a clear path to a BLA in 2H2027
- Positive: Rezolute | upLIFT interim data reignite Rezolute’s ersodetug potential in hyperinsulism following the previous sunRIZE setback
- Negative: Merck KGaA | ADAM missed on RFS for Merkel cell carcinoma, but confounding by age leaves the adjuvant avelumab question open rather than closed
- Negative: MapLight Therapeutics | ML-004 fails Phase II autism trial, but positive irritability signal found in adolescent subgroup
RESEARCH REPORTS (incl. Forecast, Thought Leadership, KOL Interview)
- Report: World Preview 2026: Big Drugs. Bigger Questions. (Link)
- Report: ASCO 2026 - Post-ASCO | 6 Key Trends | ASCO Breakthrough 2026: Key highlights
- Report: Disease Analysis - HER2+ Breast Cancer | NASH | Schizophrenia | Seasonal Influenza Vaccines
- Report: Epi & Market Forecast - IgAN | NASH | Rheumatoid Arthritis | Seasonal Influenza Vaccines
- Report: KOL Interview - Alopecia Areata | IgAN | Rheumatoid Arthritis
Latest Editorial Podcasts
